In July 2022, the Australian Medical Services Advisory Committee (MSAC) recommended the establishment of an Australian NLCSP (National Lung Cancer Screening Program), using low-dose computed tomography (LDCT) for the early detection of lung cancer in asymptomatic high-risk individuals. MSAC's recommendations for the NLCSP included core requirements as follows: (i) routine biennial screening, (ii) use of the PanCan risk prediction model for reporting baseline LDCT, and (iii) the use of the most recent version of Lung-RADS for reporting follow-up LDCT. Necessary adaptations were made to incorporate these requirements, resulting in a bespoke protocol for the Australian context. This article summarises the rationale and development of the NLCSP Nodule Management Protocol.
McCusker et al. (Fri,) studied this question.